GlobeNewswire PharmaOriginal article
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
PartnershipCNSidePositive
AI Analysis
Summary
Cerenome secured an in-network agreement with Florida Blue for its CNSide CSF tumor cell enumeration and molecular profile tests, expanding contracted payer access to approximately 164 million covered lives.
Outcome Details
In-network agreement secured with Florida Blue payer
Importance:6/10
Sentiment:
0.70
payer agreementcoverage expansiondiagnostic testoncology
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 8, 2026 11:30 AM